DSIJ Mindshare

This pharma company stock went 8 per cent high, do you own it?

With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Kiran Shroff 0 1324 Article rating: 5.0

This pharma company stock went 8 per cent high, do you own it?                                                                                                                                                                                                       With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Upcoming collaboration: Two leading pharma company stocks to watch out for

US FDA approved a benzyl alcohol and propylene glycol-free formulation to minimize gasping syndrome risk, for the treatment of seizures in newborns

Kiran Shroff 0 1946 Article rating: 4.5

Upcoming collaboration: Two leading pharma company stocks to watch out for                                                                                                                                                                                            US FDA approved a benzyl alcohol and propylene glycol-free formulation to minimize gasping syndrome risk, for the treatment of seizures in newborns.

Top-performing pharma stocks in July 2022

The pharmaceutical sector in India ranks third in terms of volume and fourteenth in terms of value (both globally).  

Sayali Kotwal 0 4078 Article rating: 3.7

The pharmaceutical sector in India ranks third in terms of volume and fourteenth in terms of value (both globally).  The domestic market is anticipated to increase three times in the next ten years, according to the Indian Economic Survey 2021.

 

RSS
12
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR